RESUMEN
INTRODUCTION: To evaluate the impact of asymptomatic meibomian gland dysfunction (MGD) on laser-assisted in situ keratomileusis (LASIK) outcomes and dry eye signs and symptoms. METHODS: A retrospective analysis of patients who underwent LASIK surgery between July 2017 and February 2018 at Care Vision Refractive Clinic, Tel Aviv, Israel, was done. Patients were divided into those who had preoperative asymptomatic significant MGD (MGD group) and those who did not have preoperative significant MGD (control group). Outcomes were the postoperative presence of punctate epithelial erosions, dry eye symptoms, the number of postoperative visits as a measure of adverse events, visual acuity, spherical equivalent, safety index, efficacy index, and the type of refractive error (myopia or hyperopia). RESULTS: A total of 497 eyes were included in this study. Both groups had similar rates of punctate epithelial erosions, 30 (12.9%) patients vs. 39 patients (14.8%) (p = 0.31); postoperative complaints of dryness, 75 patients (32.3%) vs. 90 patients (34.2%) (p = 0.36); and postoperative number of visits, 3.15 ± 0.75 vs. 3.12 ± 0.54 (p = 0.59). Uncorrected visual acuity (logMAR) at 1 month (0.026 ± 0.09 vs. 0.026 ± 0.17, p = 0.99) after surgery was similar in both groups. Mean spherical equivalent was 0.03 ± 0.17 and - 0.03 ± 0.18 (p = 0.99) in both groups. Safety index was 1.024 ± 0.06 in the clinically significant MGD group and 1.029 ± 0.07 in the control group (p = 0.45). Efficacy index was also similar in both groups (0.966 ± 0.155 and 0.979 ± 0.14, respectively, p = 0.31). No differences were found between patients with myopia and hyperopia. CONCLUSIONS: Patients with preoperative asymptomatic MGD have similar LASIK outcomes to patients without preoperative asymptomatic MGD. Accordingly, no preoperative MGD treatment or special caution is needed in these cases.
RESUMEN
OBJECTIVES: To evaluate the sex-specific effects of stimulants in children with attention-deficit/hyperactivity disorder (ADHD) on body mass index (BMI) z and height z trajectories. STUDY DESIGN: A retrospective cohort study using the database of Israel Clalit Health Services was performed. Participants included 5- to 18-year-old insured patients with documentation of at least 2 consecutive prescriptions of stimulant drugs for ADHD. Participants were further compared with sex- and age-matched insured control patients without ADHD. RESULTS: A total of 4561 (66% boys) participants with ADHD were included. Of these, 2151 (70% boys) had follow-up data for ≥2 years of treatment. A decline of ≥1 SD in height and BMI z score was observed in 10.1% and 13.2% of the cohort, respectively. During ≥2 years follow-up, boys had a greater decline in height z score (~0.2 SD) than girls (~0.06 SD). Boys' height z score continued to decline after 1 and ≥2 years, and girls' height z score declined after 1 year, and then stabilized. The trajectory of BMI z score of boys and girls was similar, showing a greater decline after 1 year, followed by an incline after ≥2 years. Younger age at stimulants initiation, better adherence, longer treatment duration, and lower socioeconomic status were correlated with a greater impact on growth attenuation. The non-ADHD group (n = 4561, 66% boys) had baseline height z score and BMI z score similar to those in children with ADHD before treatment initiation. Height z score and BMI z score were greater in children without ADHD compared with children with ADHD following 1 year of treatment (P < .001). CONCLUSIONS: These findings highlight the importance of growth monitoring accompanied with dietary counseling in children with ADHD treated with stimulants.